Safety, Efficacy and Pharmacokinetics of a New 10% Liquid Intravenous Immunoglobulin (IVIG) in Patients with Primary Immunodeficiency

INTRODUCTION: An investigational 10% liquid intravenous immunoglobulin (IVIG) was studied in 63 patients with primary immunodeficiency (PID) at 15 study sites. METHODS: Patients were treated every 3 or 4 weeks with 254–1029 mg/kg/infusion of IVIG. RESULTS: Overall, Biotest-IVIG infusions were well t...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
المؤلفون الرئيسيون: Wasserman, Richard L., Church, Joseph A., Stein, Mark, Moy, James, White, Martha, Strausbaugh, Steven, Schroeder, Harry, Ballow, Mark, Harris, James, Melamed, Isaac, Elkayam, David, Lumry, William, Suez, Daniel, Rehman, Syed M.
التنسيق: Artigo
اللغة:Inglês
منشور في: Springer US 2012
الموضوعات:
Article
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC3389237/
https://ncbi.nlm.nih.gov/pubmed/22392046
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10875-012-9656-5
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة